Although there have been individual cases of peripheral nervous system (PNS) disorders, including GBS, caused by drugs related to the IL-17 pathway (such as ixekizumab (16, 17) and ustekinumab (18)), this paper reports a potential association between secukinumab treatment and the development of GBS, which, to our knowledge, has not been previously documented. This evidence concerns the gene IL17A and Guillain-Barre syndrome.